Home - Products - Angiogenesis - JAK - Fedratinib hydrochloride hydrate

Fedratinib hydrochloride hydrate

CAS No. 1374744-69-0

Fedratinib hydrochloride hydrate( TG-101348 hydrochloride hydrate | SAR 302503 hydrochloride hydrate )

Catalog No. M23532 CAS No. 1374744-69-0

Fedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 In Stock
10MG 50 In Stock
25MG 70 In Stock
50MG 92 In Stock
100MG 110 In Stock
200MG 177 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fedratinib hydrochloride hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Fedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
  • Description
    Fedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
  • In Vitro
    ——
  • In Vivo
    Animal Model:C57Bl/6 mice induced by the JAK2V617F mutation Dosage:60 mg/kg, 120 mg/kg Administration:Oral gavage; twice daily; for 42 days Result:Showed a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis.
  • Synonyms
    TG-101348 hydrochloride hydrate | SAR 302503 hydrochloride hydrate
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK2|JAK2 (V617F)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1374744-69-0
  • Formula Weight
    615.61
  • Molecular Formula
    C27H40Cl2N6O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:120 mg/mL (194.92 mM; Need ultrasonic);H2O:97 mg/mL (157.56 mM; Need ultrasonic)
  • SMILES
    O=S(C1=CC=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O.[H]Cl.[H]Cl.[H]O[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20.
molnova catalog
related products
  • JAK-IN-5

    JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).

  • TG-46

    TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.

  • GLPG-0634

    A potent JAK1/JAK2 inhibitor with IC50 of 10 nM/28 nM in biochemical assays; less potent for JAK3 and TYK2.